GSK
GlaxoSmithKline PLC
50.50$
+0.3%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -1.2% | -8.6% | +7.1% | +1.6% | +1.3% | -7.4% | +6.3% | +7.0% | +0.8% | -11.5% | +10.2% | – | |
| – | +6.4% | -18.5% | +7.7% | +13.0% | +6.8% | -24.3% | +11.8% | +4.3% | +17.7% | -29.4% | +20.9% | – | |
| – | -4.1% | -4.3% | +6.8% | -2.6% | -1.0% | +0.4% | +4.3% | +8.0% | -5.2% | -3.5% | +6.8% | – | |
| – | +30.0% | -29.9% | +3.0% | -1.2% | +39.2% | -28.0% | +38.4% | -16.6% | +39.1% | -28.0% | +104.8% | – | |
| – | +16.6% | -22.1% | +18.1% | +54.2% | -29.9% | -22.3% | +3.4% | +4.6% | +17.9% | -19.7% | +3.9% | – | |
| – | +28.9% | -22.9% | +5.5% | +31.8% | -10.4% | -30.8% | +12.9% | -2.7% | +20.5% | -22.3% | +63.6% | – | |
| – | -70.6% | +160.0% | +10.5% | -88.5% | +268.3% | +218.4% | -8.7% | +28.2% | -41.9% | +52.3% | -79.0% | – | |
| – | +51.3% | -39.7% | +4.8% | -10.3% | -7.7% | +12.5% | +13.6% | -9.2% | +4.2% | -4.0% | +9.0% | – | |
| – | -78.8% | +257.5% | +10.3% | -95.7% | +779.7% | +274.4% | -10.5% | +30.2% | -61.3% | +125.7% | -83.5% | – | |
| – | -107.4% | – | -30.3% | -100.5% | – | +441.9% | -28.3% | +29.5% | -28.5% | +36.8% | -165.2% | – | |
| – | -76.1% | +198.9% | +12.1% | -104.9% | – | +292.3% | -11.1% | +39.5% | -68.4% | +173.1% | -75.0% | – | |
| – | -54.7% | +78.9% | +11.5% | -49.3% | -4.4% | +176.4% | +4.4% | +4.1% | -43.3% | +45.5% | +1.9% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.